Warsaw

• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr … Ended
  2022-500449-26-00 6 2023-08-03 Type 2 diabetes mellitus (T2DM)
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized … Ended
  2022-501020-19-01 5 2023-07-31 COVID-19
• UNITAS Ended
  2022-502483-21-00 4 2023-07-28 Insomnia disorder
• A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended
  2023-505627-30-00 7 2023-07-26 Solid Neoplasm
• A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel … Ended
  2022-502048-10-00 4 2023-07-21 diabetic foot ulcers
• ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended
  2022-502267-37-00 9 2023-07-17 metastatic colorectal cancer
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• Basimglurant in children, adolescents, and young adults with TSC Ended
  2024-512611-53-00 4 2023-06-30 Tuberous Sclerosis Complex
• Open-label study to assess safety and efficacy of rapamycin in drugresistant epilepsy associated with mTOR pathway pathologies Ended
  2024-515950-25-00 4 2023-06-27 epilepsy, mTORopathies, focal cortical dysplasia, LEATS
• A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended
  2022-501668-16-00 5 2023-06-26 NON SEGMENTAL VITILIGO
• A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended
  2024-515177-94-00 4 2023-06-21 Parkinson's Disease
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype … Ended
  2022-503022-13-00 5 2023-06-08 Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
• Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended
  2023-506268-15-00 5 2023-06-05 Chronic Rhinosinusitis (CRS) in Adults
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 7 2023-06-02 Head and Neck Squamous Cell Cancer
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501753-36-00 5 2023-06-02 Hidradenitis Suppurativa
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC. Ended
  2022-501047-32-00 3 2023-05-30 ULCERATIVE COLITIS
• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended
  2023-509471-17-00 4 2023-05-24 Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
• Study of M5049 in DM and PM Participants (NEPTUNIA) Ended
  2022-501351-82-00 4 2023-05-23 Dermatomyositis, Polymyositis
• A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera … Ended
  2022-502575-30-00 5 2023-05-23 Atopic Dermatitis
• A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended
  2023-509747-27-00 4 2023-05-18 Heart failure
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia

Showing 1,465–1,488 of 1,708 trials